Dialysed patients suffering from chronic kidney disease (CKD) show varied levels of concentration of parathyroid hormone (PTH) in the blood. One of the factors in charge of regulating levels of PTH concentration is 1,25-dihydroxycholecalciferol [1,25-(OH)2D3]. Its deficiency in advanced stages of CKD is common. Vitamin D supplementation is not always effective in reaching levels of PTH concentration recommended by KDIGO for the dialysed patients. That suggests, among other things, disturbances in 1,25-(OH)2D3, reaching its place of target effect and having the desired final result. Disturbances of vitamin D target pathway can be genetically conditioned, hence the aim of this paper is to describe the distribution of polymorphic variants of vitamin D-binding protein gene (VDBP), vitamin D receptor gene (VDR) and gene of the calcium-sensing receptor (CaSR) with respect to PTH concentrations in serum and response to cinacalcet treatment in patients with secondary hyperparathyroidism in view of the differences in demographical, clinical and laboratory data of the dialysed patients.